Ken Liu1,2,3,4, Vincent Wai-Sun Wong1,2,3, Keith Lau1,2,3, Sienna Du Liu1,2,3, Yee-Kit Tse1,2,3, Terry Cheuk-Fung Yip1,2,3, Raymond Kwok1,2,3, Alex Yiu-Wa Chan1,2,3, Henry Lik-Yuen Chan1,2,3, Grace Lai-Hung Wong1,2,3. 1. Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong,China. 2. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong,China. 3. State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong,China. 4. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: Liver stiffness measurement (LSM) by transient elastography (TE) has been shown to predict outcomes in patients with liver disease. While controlled attenuation parameter (CAP) measurement can accurately quantify hepatic steatosis, its prognostic value is unknown. We aim to determine if CAP is predictive for liver-related events (LRE), non-hepatocellular carcinoma (HCC) cancers, and cardiovascular events (CVE). METHODS: Consecutive patients with both a reliable LSM and ≥10 successful CAP measurements by TE from August 2012 to March 2016 were included in the analysis. LRE were defined as HCC or hepatic decompensation. CVE were defined as acute coronary syndrome (ACS), cerebrovascular accident (CVA), or coronary intervention (stenting or bypass). RESULTS: Of the 5,848 patients that were examined, 4,282 (56.7% male, median age 57 years) had adequate follow-up, reliable LSM (median 6.1 kPa), and ≥10 CAP measurements (median 250 dB/m). Indications for TE were: suspected non-alcoholic fatty liver disease (NAFLD) (40.7%), hepatitis B (HBV) (37.0%), hepatitis C (2.9%), and others (19.4%). During 8,540 patient-years of follow-up, there were 45 patients with LRE (34 HCC, 33 decompensations), 73 with newly diagnosed non-HCC cancers, and 65 with CVE (27 ACS, 25 CVA, and 35 coronary interventions). CAP did not predict LRE, non-HCC cancer, or CVE on univariate analysis. On multivariate analysis, LSM, male sex, platelet count, serum albumin, and HBV etiology independently predicted LRE; age was the only independent predictor of non-HCC cancer; while age, fasting blood glucose, total cholesterol, and creatinine predicted for CVE. Subgroup analyses of viral hepatitis and NAFLD patients revealed similar results. CONCLUSION: Neither the presence nor the severity of hepatic steatosis as measured by CAP predict LRE, cancer, or CVE in the short term.
OBJECTIVES:Liver stiffness measurement (LSM) by transient elastography (TE) has been shown to predict outcomes in patients with liver disease. While controlled attenuation parameter (CAP) measurement can accurately quantify hepatic steatosis, its prognostic value is unknown. We aim to determine if CAP is predictive for liver-related events (LRE), non-hepatocellular carcinoma (HCC) cancers, and cardiovascular events (CVE). METHODS: Consecutive patients with both a reliable LSM and ≥10 successful CAP measurements by TE from August 2012 to March 2016 were included in the analysis. LRE were defined as HCC or hepatic decompensation. CVE were defined as acute coronary syndrome (ACS), cerebrovascular accident (CVA), or coronary intervention (stenting or bypass). RESULTS: Of the 5,848 patients that were examined, 4,282 (56.7% male, median age 57 years) had adequate follow-up, reliable LSM (median 6.1 kPa), and ≥10 CAP measurements (median 250 dB/m). Indications for TE were: suspected non-alcoholic fatty liver disease (NAFLD) (40.7%), hepatitis B (HBV) (37.0%), hepatitis C (2.9%), and others (19.4%). During 8,540 patient-years of follow-up, there were 45 patients with LRE (34 HCC, 33 decompensations), 73 with newly diagnosed non-HCC cancers, and 65 with CVE (27 ACS, 25 CVA, and 35 coronary interventions). CAP did not predict LRE, non-HCC cancer, or CVE on univariate analysis. On multivariate analysis, LSM, male sex, platelet count, serum albumin, and HBV etiology independently predicted LRE; age was the only independent predictor of non-HCC cancer; while age, fasting blood glucose, total cholesterol, and creatinine predicted for CVE. Subgroup analyses of viral hepatitis and NAFLDpatients revealed similar results. CONCLUSION: Neither the presence nor the severity of hepatic steatosis as measured by CAP predict LRE, cancer, or CVE in the short term.
Authors: M Soresi; S Tripi; V Franco; L Giannitrapani; A Alessandri; F Rappa; O Vuturo; G Montalto Journal: Liver Int Date: 2006-11 Impact factor: 5.828
Authors: Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Steven Woon-Choy Tsang; Tina Fan; Winnie Chiu-Wing Chu; Jean Woo; Anthony Wing-Hung Chan; Paul Cheung-Lung Choi; Angel Mei-Ling Chim; James Yun-Wong Lau; Francis Ka-Leung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan Journal: Gut Date: 2011-02-21 Impact factor: 23.059
Authors: H L-Y Chan; G L-H Wong; P C-L Choi; A W-H Chan; A M-L Chim; K K-L Yiu; F K-L Chan; J J-Y Sung; V W-S Wong Journal: J Viral Hepat Date: 2008-07-28 Impact factor: 3.728
Authors: Mary C White; Dawn M Holman; Jennifer E Boehm; Lucy A Peipins; Melissa Grossman; S Jane Henley Journal: Am J Prev Med Date: 2014-03 Impact factor: 5.043
Authors: Georg Semmler; Judith Stift; Bernhard Scheiner; Katharina Wöran; Philipp Schwabl; Rafael Paternostro; Theresa Bucsics; Albert Friedrich Stättermayer; Matthias Pinter; Arnulf Ferlitsch; Michael Trauner; Thomas Reiberger; Mattias Mandorfer Journal: Dig Dis Sci Date: 2019-06-17 Impact factor: 3.199
Authors: Bernhard Scheiner; Lisa Steininger; Georg Semmler; Lukas W Unger; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; Arnulf Ferlitsch; Michael Trauner; Thomas Reiberger; Mattias Mandorfer Journal: Liver Int Date: 2018-09-22 Impact factor: 5.828